Antipsychotics in clinical practice. The refractory schizophrenic patients treatment;Leki przeciwpsychotyczne w praktyce lekarza psychiatry. Leczenie pacjentów z rozpoznaniem schizofrenii lekoopornej

Psychiatria Polska

Volumn 42, Issue 6, 2008, Pages 859-873

  Meder, Joanna ^a,e   Tyszkowska, Magdalena ^d   Jarema, Marek ^b   Araszkiewicz, Aleksander ^c   Szafrański, Tomasz ^b  

^a Klinika Rehabilitacji IPiN W Warszawie   (Poland)

^b III Klinika Psychiatryczna IPiN W Warszawie   (Poland)

^c Klinika Psychiatrii Collegium Medium W Bydgoszczy   (Poland)

^d Janssen Cilag   (Poland)

^e INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Atypicals; Making treatment decision; Refractory schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZUCLOPENTHIXOL; BENZODIAZEPINE DERIVATIVE; FLUOXETINE; SEROTONIN ANTAGONIST;

ARTICLE; CLINICAL PRACTICE; DRUG CHOICE; DRUG COST; HOSPITAL PATIENT; HUMAN; NORMAL HUMAN; OUTPATIENT; POLAND; PRESCRIPTION; QUESTIONNAIRE; REIMBURSEMENT; SCHIZOPHRENIA; STRUCTURED INTERVIEW; DOSE RESPONSE; DRUG ADMINISTRATION; ECONOMICS; HEALTH PERSONNEL ATTITUDE; PRACTICE GUIDELINE; PSYCHOLOGY; RECURRENT DISEASE; STATISTICS;

ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FLUOXETINE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; POLAND; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN ANTAGONISTS;

EID: 66349099653     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Jarema M, Kiejna A, Landowski J, Meder J, Rabe-Jabłońska J, Rybakowski J. Standardy leczenia farmakologicznego schizofrenii. Psychiatr. Pol. 2006; 40: 1171-1205.
2. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Mooler HJ. WFSBP task force on treatment guidelines for schizophrenia. WFSBP guidelines for biological treatment of schizophrenia. Part 1: Acute treatment of schizophrenia. World J. Biol. Psychiatry 2005; 6(3): 132-191.
3. Brenner HD, Merlo MCG. Definition of therapy-resistant schizophrenia and its assessment. Eur. Psychiatry 1995; 10, supl. 1: 11-17.
4. National Institute for Clinical Excellence. Core interventions in the treatment and management of schizophrenia. 2003, Nice, London, www.nice.org.uk
5. Marder S. Defining and characterising treatment-resistant schizophrenia. Eur. Psychiatry 1995; 10, supl. 1: 7-10.
6. Kane JM, Honigfeld G, Singer J, Meltzer H, and the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: A double blind comparison versus chlorpromazine/benztropine. Arch. Gen. Psychiatry 1988; 45: 789.
7. Taylor CG, Flynn SW, Altman S, Ehmann T, MacEwan GW, Honer WG. An open trial of risperidone augmentation of partial response to clozapine. Schizophr. Res. 2001; 48: 155-158.
8. Chan J, Sweeting M. Combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. J. Psychopharmacol. 2007; 21(6): 657-664. (Pubitemid 47472722)
9. Lindenmayer JP, Volavka J, Lieberman J, i in. Olanzapina for schizophrenia refractory to typical and atypical antipsychotics: An open-label, prospective trial. J. Clin. Psychopharmacol. 2001; 21, 4.
10. Kane JM, Khanna S, Rajadhyaksha S, Giller E. Efficacy and tolerability of ziprasidon in patients with treatment-resistant schizophrenia. Int. Clin. Psychopharmacol. 2006; 21: 21-28.
11. Sacchetti E, Panariello A, Regini C, Valsecchi Pa̧ Quetiapina in hospitalized patients with schizophrenia refractory to treatment with first-generation antipsychotics: a 4-week, flexible-dose, single-blind, exploratory, pilot trial. Schizophr. Res. 2004; 69: 325-334.
12. Kane JM, Meltzer HY, Carson WH, McQuade RD, Marcus RN, Sanchez R. Aripiprazol Study Group: Aripiprazol for the treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J. Clin. Psychiatry 2007; 68, 2. (Pubitemid 47313647)